DAWN Rises on Promising Phase 2 data in pLGG
Market News

DAWN Rises on Promising Phase 2 data in pLGG

Shares of biopharmaceutical company Day One Biopharmaceuticals (NASDAQ:DAWN) are on the up move today after it announced data from a phase 2 study evaluating its investigational candidate tovorafenib (DAY-101). Additionally, the company has also initiated a rolling new drug application (NDA) for DAY-101 with the U.S. Food and Drug Administration (FDA) as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).

The rolling submission allows the company to submit parts of the application and have them reviewed on an ongoing basis. The submission is expected to be completed in October 2023.

In the Phase 2 study, DAY-101 was observed to be well-tolerated with clinically meaningful responses in subjects. Further, the therapy demonstrated an overall response rate of 67% with a clinical benefit rate of 93%.

DAY-101 has already received breakthrough therapy and rare pediatric disease designation in the U.S. alongside an orphan drug designation in the U.S. as well as Europe.

Overall, the Street has a $37 consensus price target on DAWN alongside a Moderate Buy consensus rating. Today’s price gains come on top of a nearly 8.5% climb in DAWN shares over the past five sessions.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles